1. Home
  2. GKOS vs ORN Comparison

GKOS vs ORN Comparison

Compare GKOS & ORN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • ORN
  • Stock Information
  • Founded
  • GKOS 1998
  • ORN 1994
  • Country
  • GKOS United States
  • ORN United States
  • Employees
  • GKOS N/A
  • ORN N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • ORN Military/Government/Technical
  • Sector
  • GKOS Health Care
  • ORN Industrials
  • Exchange
  • GKOS Nasdaq
  • ORN Nasdaq
  • Market Cap
  • GKOS 5.8B
  • ORN 350.4M
  • IPO Year
  • GKOS 2015
  • ORN 2007
  • Fundamental
  • Price
  • GKOS $103.82
  • ORN $8.58
  • Analyst Decision
  • GKOS Strong Buy
  • ORN Strong Buy
  • Analyst Count
  • GKOS 13
  • ORN 2
  • Target Price
  • GKOS $135.15
  • ORN $11.25
  • AVG Volume (30 Days)
  • GKOS 826.6K
  • ORN 353.7K
  • Earning Date
  • GKOS 07-30-2025
  • ORN 07-29-2025
  • Dividend Yield
  • GKOS N/A
  • ORN N/A
  • EPS Growth
  • GKOS N/A
  • ORN N/A
  • EPS
  • GKOS N/A
  • ORN 0.08
  • Revenue
  • GKOS $404,523,000.00
  • ORN $824,375,000.00
  • Revenue This Year
  • GKOS $27.88
  • ORN $4.34
  • Revenue Next Year
  • GKOS $27.60
  • ORN $11.09
  • P/E Ratio
  • GKOS N/A
  • ORN $108.83
  • Revenue Growth
  • GKOS 23.92
  • ORN 15.58
  • 52 Week Low
  • GKOS $77.10
  • ORN $4.64
  • 52 Week High
  • GKOS $163.71
  • ORN $12.12
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 57.69
  • ORN 46.81
  • Support Level
  • GKOS $101.30
  • ORN $8.62
  • Resistance Level
  • GKOS $106.82
  • ORN $9.61
  • Average True Range (ATR)
  • GKOS 3.17
  • ORN 0.36
  • MACD
  • GKOS 0.19
  • ORN -0.10
  • Stochastic Oscillator
  • GKOS 72.45
  • ORN 5.50

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About ORN Orion Group Holdings Inc. Common

Orion Group Holdings Inc is a specialty construction company serving the infrastructure, industrial, and building sectors, providing services both on and off the water in the continental United States, Alaska, Canada and the Caribbean Basin through its marine segment and its concrete segment. Its marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar and mesh across the light commercial, structural and other associated business areas.

Share on Social Networks: